Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.

Cedric LebacleKarim BensalahJean-Christophe BernhardLaurence AlbigesBrigitte LaguerreMarine Gross-GoupilHerve BaumertHerve LangThibault TricardBrigitte DuclosArmelle ArnouxCeline PiedvacheJean-Jacques PatardBernard Escudier

Published in: BJU international (2018)

Neoadjuvant axitinib in cT2 ccRCC is feasible and, even with a modest decrease in size, allowed a tumour shrinkage <7 cm in 12 cases; however, PN procedures remained complex, requiring surgical expertise with possible morbidity.

Keyphrases

phase ii study
locally advanced
image quality
dual energy
computed tomography
contrast enhanced
rectal cancer
open label
metastatic renal cell carcinoma
positron emission tomography
squamous cell carcinoma
lymph node
magnetic resonance imaging
radiation therapy
clinical trial
magnetic resonance
placebo controlled